Global Partnership to Bolster Singapore's Biotech Innovation Engine

SINGAPORE – April 09, 2026 – In a significant move to accelerate life sciences innovation, Singapore's NSG Bio and global scientific giant Charles River Laboratories have signed a Memorandum of Understanding (MOU) to create a more integrated and powerful support system for the nation's burgeoning biotech sector. The agreement, formalized during Charles River's APAC Biomanufacturing Leadership Summit 2026, signals a shared commitment to smoothing the complex journey from laboratory discovery to market-ready therapeutics.

The collaboration unites NSG Bio's extensive purpose-built infrastructure and vibrant community platform with Charles River's world-renowned portfolio of drug discovery and development services. This strategic alliance aims to provide biotech startups and scaling companies with a more streamlined pathway, reducing friction and enabling them to reach critical development milestones with greater efficiency and scientific rigor.

A Strategic Alliance for a Growing Hub

At its core, the partnership is designed to bridge a critical gap in the biotech development lifecycle. NSG Bio has already established itself as an "ecosystem catalyst" in Singapore, providing over 40 companies with access to 70,000 square feet of state-of-the-art, certified BSL-2 laboratory and office space across key biomedical clusters like Biopolis and Singapore Science Park. This model allows companies to operate with capital efficiency, leveraging shared equipment and a collaborative environment.

However, as these companies advance their research, they require increasingly specialized and complex services that often fall outside the scope of a typical incubator. This is where Charles River's expertise becomes pivotal. With a global network and deep capabilities in crucial areas like cell banking, cell line characterization, and protein characterization, Charles River provides the validation and testing services necessary to de-risk scientific assets and prepare them for regulatory scrutiny.

"From the beginning, NSG Bio's main goal has always been simple but important: to empower the biotech community, not only within NSG Bio but also across the broader Singapore ecosystem," said Hasyim Sim, Chief Operating Officer of NSG Bio. "With the signing of this Memorandum of Understanding with Charles River, we are taking another meaningful step forward... NSG BioLabs will be better positioned to support our community end-to-end from infrastructure and tools to specialized services, products, and scientific expertise."

This sentiment is echoed by Charles River, which views the partnership as a way to deepen its engagement with Singapore's dynamic innovation landscape. "We are excited to deepen our partnership with NSG Bio as we continue to support the growth of the biotech industry in Singapore," stated Kerstin Dolph, Senior Vice President, Manufacturing at Charles River. "Utilizing our biologics expertise, we help organizations become more efficient as they move from initial research to key development milestones."

Addressing Critical Bottlenecks for Startups

For the scientists and entrepreneurs on the front lines of innovation, the collaboration promises to alleviate several persistent pain points. One of the most significant challenges for early-stage biotech firms is the so-called "valley of death"—the funding gap between initial seed investment and later-stage venture capital. Investors are increasingly risk-averse, demanding robust data packages and clear evidence of a product's viability before committing significant capital.

By providing easier access to Charles River's industry-standard characterization and testing services, the partnership enables startups to generate the high-quality, validated data needed to attract further investment. This integration of infrastructure and specialized services allows young companies to build a more compelling case for their technology, effectively de-risking their projects in the eyes of potential funders and partners. The startups housed within NSG Bio, which have already collectively raised nearly US$400 million, stand to gain a considerable advantage in securing their next tranches of funding.

Furthermore, the alliance helps relieve the immense operational burden on small R&D teams. Instead of spending precious time and resources sourcing, vetting, and managing multiple external service providers, startups can now tap into a connected ecosystem. This allows founders and scientists to maintain focus on their core mission: advancing their science. The MOU outlines plans for ecosystem enablement initiatives, including shared learning sessions and knowledge exchange, which will further equip these companies with the expertise needed to navigate the complex path to commercialization.

Bolstering Singapore's National Ambition

This partnership is more than a private sector agreement; it is a powerful endorsement of Singapore's decades-long strategy to establish itself as a premier global hub for biomedical sciences. The Singaporean government has consistently invested in the sector through ambitious, multi-billion-dollar initiatives like the Research, Innovation and Enterprise (RIE) plans. The current RIE2025 plan, and the forthcoming RIE2030 strategy, emphasize building a vibrant, self-sustaining ecosystem that can translate cutting-edge research into economic and societal impact.

The NSG Bio and Charles River collaboration aligns perfectly with this national vision. By fostering a more robust and interconnected local ecosystem, it makes Singapore an even more attractive destination for international biotech investment and world-class scientific talent. The city-state's reputation for political stability, strong intellectual property protection, and a clear regulatory framework has already drawn major pharmaceutical and biotech players. This new alliance strengthens the grassroots of that ecosystem, ensuring a steady pipeline of innovative startups can grow and thrive.

NSG Bio's success is a testament to the fertile ground Singapore provides. Since its founding in 2019, it has become the largest provider of private biotech co-working labs and has nurtured companies working on everything from precision medicine to AI-driven drug discovery. This new layer of support from a global leader like Charles River is set to amplify that impact, potentially accelerating the timeline for Singapore-born innovations to reach patients worldwide.

A Blueprint for Biomanufacturing Support in APAC

The choice of venue for the signing—the APAC Biomanufacturing Leadership Summit—is particularly telling. It positions the partnership not just as a local initiative, but as a potential blueprint for the broader Asia-Pacific region. As countries across APAC seek to build their own life sciences capabilities, particularly in the high-value area of biomanufacturing, the integrated model pioneered by NSG Bio and Charles River offers a compelling template.

The model demonstrates how to effectively combine local infrastructure and community-building with globally recognized scientific and regulatory expertise. This synergy is crucial for creating an ecosystem that can support companies throughout the entire value chain, from initial discovery to complex manufacturing processes. The MOU's focus on strengthening pathways between early R&D and downstream development activities directly addresses a key challenge for the region's biomanufacturing ambitions.

Under the agreement, the two organizations will explore opportunities to connect startups with a wide array of partners and resources that support efficient scaling. This network-centric approach, combined with access to top-tier expertise, could help cultivate a more resilient and competitive biopharmaceutical industry across Asia. As the partnership evolves and specific initiatives are rolled out, industry observers throughout the region will be watching closely to see the tangible results of this powerful collaboration.